Q3 19 turned out to be another impressive quarter for Novartis. The group clocked 13% constant currency growth, resulting in a second consecutive guidance upgrade during the year. Innovative Medicines led the growth (+16% vs. +9% in Q2 19), well supported by the recovering Sandoz segment (+5% vs. +3% in Q2 19). Overall, the pharma giant remains a beneficiary of a diversified asset base and pipeline, and well-proven executional capabilities.
24 Oct 2019
Sustained stellar performance prompts another guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sustained stellar performance prompts another guidance upgrade
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
24 Oct 2019 -
Author:
Surbhit Gupta -
Pages:
4
Q3 19 turned out to be another impressive quarter for Novartis. The group clocked 13% constant currency growth, resulting in a second consecutive guidance upgrade during the year. Innovative Medicines led the growth (+16% vs. +9% in Q2 19), well supported by the recovering Sandoz segment (+5% vs. +3% in Q2 19). Overall, the pharma giant remains a beneficiary of a diversified asset base and pipeline, and well-proven executional capabilities.